Inflammation drives atherosclerosis development and progression, and the crucial proof came from the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial, which demonstrated that targeting IL-1β with the neutralizing antibody canakinumab leads to a significant decrease in cardiovascular events compared to patients treated with a placebo [127]. Here, IL1B is linked to atherosclerosis.